( MENAFN - PR Newswire) Aadi Enters into Exclusive License for Three-Asset ADC Portfolio Developed through a Collaboration between WuXi Biologics and HANGZHOU DAC Aadi Enters Agreement to Sell FYARRO® and Associated Infrastructure to KAKEN Pharmaceutical for $100M; Announces PIPE Financing of $100M Cumulative Capital Expected to Fund Operations into Late 2028, Including Anticipated Clinical Data for the ADC Portfolio Co-Founder and Former CEO of ProfoundBio, Baiteng Zhao, Appointed to Aadi Board of Directors Aadi to Hold Webcast and Conference Call on December 20 at 8:00 AM EST LOS ANGELES, Dec. 19, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI ) today announced it has entered into an exclusive license agreement for development and global commercialization of a three-asset portfolio of preclinical, next-wave antibody-drug conjugates (ADCs), in collaboration with WuXi Biologics (2269), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and HANGZHOU DAC BIOTECHNOLOGY CO., LTD. (HANGZHOU DAC), a global leader in ADC innovation. Per the terms of the license agreement, Aadi is granted exclusive rights to certain patents and know-how pertaining to three preclinical ADC programs leveraging HANGZHOU DAC's CPT113 linker payload technology targeting each of Protein Tyrosine Kinase 7 (PTK7), Mucin-16 (MUC16) and Seizure Related 6 Homolog (SEZ6). Aadi will pay aggregate upfront payments of $44 million for in-licensing such ADC programs. Additionally, Aadi is obligated to pay cumulative development milestone payments of up to $265 million, cumulative commercial milestone payments of up to $540 million and single-digit royalties of sales. To support this transaction, Aadi entered into a subscription agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $100 million, before deducting placement agent fees and other offering expenses. The Company is selling an aggregate of 21,592,000 shares of its common stock ("Common Stock") at a price of $2.40 per share, representing a premium of approximately 3.4% to the closing price on December 19, 2024 on Nasdaq, and pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 20,076,500 shares of Common Stock at a purchase price of $2.3999 per Pre-Funded Warrant share. The syndicate was led by Ally Bridge Group, with participation from new investors OrbiMed, Invus, Kalehua Capital and other accredited investors, Tae Han co-founder of ProfoundBio, as well as existing investors, including Avoro Capital, KVP Capital and Acuta Capital Partners. The PIPE financing is expected to close in the first half of 2025, subject to stockholder vote and satisfaction of customary closing conditions. "I'm thrilled to announce our partnership with WuXi Biologics and HANGZHOU DAC to bring forward this thoughtfully selected ADC portfolio. We were deliberate in identifying broadly expressed tumor targets where first-generation ADCs have already shown proof of concept. With our next wave ADC portfolio, we aim to build upon these earlier therapies to deliver improved outcomes for people living with cancer," said David Lennon, PhD, President and CEO of Aadi Bioscience. "The financing underscores the confidence our investors have in both the potential of this portfolio and the strength of Aadi's management team." About the ADC Portfolio Each of the three ADC assets utilizes HANGZHOU DAC's CPT113 ADC platform, which consists of a highly stable yet cleavable linker that delivers a Topoisomerase I (TOPO1) inhibitor payload. The CPT113 platform's linker stability and novel payload has the potential to be highly competitive among the next generation ADC platforms. To effectively leverage the CPT113 platform, Aadi selected tumor targets that are upregulated in high-potential cancer indications and where clinical efficacy has been demonstrated by first-generation ADCs. These assets were discovered through the collaborative efforts of WuXi Biologics and HANGZHOU DAC, utilizing the innovative antibody discovery platform provided by WuXi Biologics and advanced linker-payload technology provided by HANGZHOU DAC. "Leveraging our advanced antibody discovery service, we're glad to enable Aadi to accelerate the discovery of precision therapies targeting some of the most challenging cancers," said Dr. Chris Chen, CEO of WuXi Biologics. "This collaboration underscores our wide recognition as an industry leader in discovery service solutions, and further validates our ability to provide integrated discovery technology platforms for global partners to develop next-generation modalities. We look forward to partnering with Aadi and HANGZHOU DAC to expeditiously move these assets forward into clinical development and benefit patients worldwide." "HANGZHOU DAC's CPT-ADC platform is designed to enable next wave ADC capabilities that surpass first-generation technologies, including two programs already in clinical development in China," said Dr. Robert Y. Zhao, President and CEO of HANGZHOU DAC Biotechnology. "As a global leader in ADC innovation, we are excited to partner with Aadi and WuXi Biologics to deliver this promising portfolio to patients." Aadi to Sell FYARRO for $100 Million, Cumulative Capital Expected to Fund Operations into Late 2028 In a separate agreement, KAKEN Pharmaceutical Co., Ltd., an R&D driven pharmaceutical company in Japan, has entered into a stock purchase agreement under which KAKEN will acquire Aadi Subsidiary, Inc. and all of its assets, including FYARRO® (sirolimus protein-bound particles for injectable suspension) (albumin-bound) and associated infrastructure, including the majority of Aadi employees who support the FYARRO® business. FYARRO is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa), with cumulative revenue of $25.2 million reported over the prior four quarters ended September 30, 2024. Per the terms of the agreement, Kaken will pay Aadi $100 million in cash at closing, subject to certain adjustments. The transaction is expected to close in the first half of 2025, subject to Aadi stockholder approval and certain closing conditions. Upon the closing of this transaction, KAKEN will also acquire the rights to the Aadi name and trademark. "We are enormously proud of the impact FYARRO has had for people with PEComa, and Kaken's capabilities, coupled with the proven track record of the Aadi team, ensures physicians and patients will continue to have access to this critical treatment," said Lennon. The net proceeds from the PIPE financing and the sale of FYARRO, together with the Company's existing cash, cash equivalents and marketable securities are expected to fund operations into late-2028, including anticipated clinical data readouts for the ADC portfolio. Baiteng Zhao Appointed to the Board of Directors, Brings Significant ADC Expertise Baiteng Zhao, PhD, joins Aadi's board of directors. Zhao co-founded ProfoundBio, a clinical stage next-gen ADC developer, in 2018 and served as the Chairman and CEO of the company until it was acquired by Genmab for $1.8 billion in May 2024. Prior to ProfoundBio, Dr. Zhao worked at Seagen (now part of Pfizer) for more than eight years and was responsible for the modeling and simulation strategies for the development pipeline and supported preclinical and clinical development of ADC drug candidates. "We are delighted to welcome Baiteng to our Board. His deep expertise and successful track record in ADC development will be instrumental as we tenaciously move this exciting portfolio forward," said Caley Castelein, MD, Chair of the Board of Directors of Aadi Bioscience. "I am thrilled to join the Board at this pivotal moment for Aadi," said Baiteng Zhao, PhD, Board of Directors of Aadi Bioscience and co-founder of ProfoundBio. "PTK7, MUC16 and SEZ6 represent highly promising targets that are commonly overexpressed in cancers with significant unmet therapeutic needs. Coupled with an advanced linker-payload platform that has the potential to enable next-gen ADCs, I believe Aadi is uniquely positioned to make a meaningful impact on patient outcomes. I look forward to collaborating with the leadership team and fellow Board directors to advance these innovative programs and drive transformative progress for patients." Advisors Leerink Partners is serving as financial advisor to Aadi on the sale of FYARRO and the licensing of the ADC portfolio. Jefferies LLC is acting as exclusive placement agent for the PIPE financing. Wilson Sonsini Goodrich & Rosati, P.C. is serving as legal counsel to Aadi. McDermott Will & Emery LLP is serving as legal counsel to Kaken. Cooley LLP is serving as legal counsel to Jefferies LLC. Nomura Securities Co., Ltd. is serving as financial advisor to KAKEN. Conference Call Information The Aadi management team is hosting a conference call and webcast tomorrow, Friday, December 20th at 8:00 AM EST (5:00 AM PST) to discuss these updates. Participants may access a live webcast of the call and the associated slide presentation on these data through the "Investors & News" page of the Aadi Bioscience website at aadibio. To participate via telephone, please register in advance at this link . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the Company's website for at least 30 days. Additional Information for Stockholders This communication relates to the proposed sale of FYARRO and the proposed PIPE financing and may be deemed to be solicitation material in respect of such transactions. In connection with these proposed transactions, Aadi will file a Proxy Statement with the SEC. This communication is not a substitute for the Proxy Statement or any other documents that Aadi may file with the SEC or send to Aadi stockholders in connection with the proposed transactions. Before making any voting decision, investors and securityholders are urged to read the Proxy Statement and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transactions as they become available because they will contain important information about the proposed transactions and related matters. Stockholders may obtain a copy of the Proxy Statement and other documents the Company files with the SEC (when they are available) through the website maintained by the SEC at , as well as on the Investor and News section of Aadi's website at . Certain stockholders of Aadi holding approximately 36% of Aadi's outstanding shares, as of the date hereof, including members of its board of directors and related entities, have entered into voting and support agreements in favor of KAKEN Pharmaceutical and Aadi, pursuant to which such stockholders have agreed to vote in favor of the stock purchase transaction with KAKEN Pharmaceutical and the other transactions described above. Participants in the Solicitation Aadi and its respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Aadi in connection with the proposed transactions. Information about Aadi's directors and executive officers is set forth in Aadi's definitive proxy statement filed with the SEC on April 26, 2024, and in subsequent filings made by Aadi with the SEC. Other information regarding the interests of such individuals, as well as information regarding Aadi's directors and executive officers and other persons who may be deemed participants in the proposed transactions, will be set forth in the Proxy Statement and other relevant materials to be filed with the SEC when they become available. You may obtain free copies of these documents as described in the preceding paragraph. No Offer or Solicitation This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor a solicitation of any vote or approval with respect to the proposed transactions or otherwise, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. The offer and sale of securities of Aadi described above are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended, and may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements. Concurrently with the execution of the subscription agreement, the Company and the investors entered into a registration rights agreement pursuant to which the Company has agreed to file, following the closing of the PIPE financing, a registration statement with the SEC registering the resale of the shares of Common Stock and the shares of Common Stock underlying the Pre-Funded Warrants sold in the PIPE financing. About Aadi Bioscience Aadi is a precision oncology company with a vision to make bold choices in applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to-treat cancers. More information on the Company is available on the Aadi website at and connect with us on LinkedIn. Forward-Looking Statements This press release contains certain forward-looking statements regarding the business of Aadi Bioscience that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the Company's current beliefs and expectations and may include, but are not limited to, statements relating to: the timing and completion of the proposed sale of FYARRO to Kaken Pharmaceuticals and the anticipated timing of the closing of the transaction; expectations regarding the timing, closing and completion of the PIPE financing; Aadi's expected cash position at the closing and cash runway of the company following the sale of FYARRO and PIPE financing; the future operations of Aadi; the development and potential benefits of any of Aadi's product candidates, including the preclinical ADC assets proposed to be licensed from WuXi; anticipated preclinical and clinical development activities and related timelines, including the expected timing for announcement of data and other preclinical and clinical results and potential submission of IND filings for one or more product candidates; and other statements that are not historical fact. Actual results could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks associated with (i) the risk that the conditions to the closing of the proposed sale of FYARRO or the PIPE financing are not satisfied, including the failure to timely obtain stockholder approval for the transactions, if at all; (ii) uncertainties as to the timing of the consummation of the proposed transactions and the ability of each of Kaken and Aadi to consummate the proposed sale of FYARRO; (iii) risks related to Aadi's ability to manage its operating expenses and its expenses associated with the proposed transactions pending the closing; (iv) risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the proposed transactions; (v) unexpected costs, charges or expenses resulting from the transactions; (vii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed sale of FYARRO or the proposed PIPE financing; (vii) the uncertainties associated with Aadi's product candidates, as well as risks associated with the preclinical and clinical development and regulatory approval of product candidates, including potential delays in the completion of preclinical studies and clinical trials; (viii) risks related to the inability of Aadi to obtain sufficient additional capital to continue to advance these product candidates; (ix) uncertainties in obtaining successful preclinical and clinical results for product candidates and unexpected costs that may result therefrom; (x) risks related to the failure to realize any value from product candidates being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; and (xi) risks associated with the possible failure to realize certain anticipated benefits of the proposed sale of FYARRO or the proposed PIPE financing, including with respect to future financial and operating results. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including under the caption "Item 1A. Risk Factors," and in Aadi's subsequent Quarterly Reports on Form 10-Q, and elsewhere in Aadi's reports and other documents that Aadi has filed, or will file, with the SEC from time to time and available at . All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Aadi undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This cautionary statement is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Contact: [email protected] SOURCE Aadi Bioscience MENAFN19122024003732001241ID1109014329 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
AP Trending SummaryBrief at 5:06 p.m. ESTKate Wyler’s political future takes a dramatic turn in 'The Diplomat' Season 3Los Angeles Chargers quarterback Justin Herbert missed Wednesday’s practice due to a sprained left ankle and a thigh contusion that he suffered in the team’s game against AFC West rival, Kansas City Chiefs. The ankle injury came early in the first quarter and the contusion happened just before the half. Despite the injury, Herbert remained in the game, completing the series following a brief medical timeout. The training staff provided immediate treatment, retaping his ankle to alleviate the discomfort. Justin Herbert Returns To Chargers Practice After that practice, Herbert told the media that he felt pain in his ankle and thigh while on the sidelines. He explained he felt the pain when “rotating and kind of stepping through the throw.” This resulted in a limited offensive attack for the remainder of the game. But on Thursday, Herbert was back to practice. At the time of the writing of this article, it is unclear if Herbert is a full participant, but his return is good news for the team nonetheless as they prepare to face the Tampa Bay Buccaneers this Sunday. Herbert also relayed to the media that the pain he is feeling from this ankle injury is not as intense as he felt earlier in the season when he was dealing with an injury to his right ankle. Some speculated that Herbert’s slow start to the year could be, at least, in part due to that initial ankle injury. While Herbert’s arm is the biggest asset connected to the health of his legs, the Chargers have also come to rely heavily on his rushing ability. His 224 yards are the third most among all Chargers runners and he has also picked up 20 percent of the team’s rushing first downs, which has kept this team afloat while they have struggled to run the ball recently. While this is good news for the Chargers, their offense will need to find answers for other injuries on their side of the ball. A part of their rushing struggles is due to top running back JK Dobbins missing time on the injured reserve. Missing their top two receivers, Ladd McConkey and Will Dissly, was very apparent against the Chiefs. McConkey has been limited in practice, while Dissly has not participated. This article first appeared on LAFB Network and was syndicated with permission.
TORONTO — Broad-based gains led Canada's main stock index higher in late-morning trading on Christmas Eve, while U.S. stock markets also rose. The S&P/TSX composite index was up 57.82 points at 24,806.80. In New York, the Dow Jones industrial average was up 177.64 points at 43,084.59. The S&P 500 index was up 43.11 points at 6,017.18, while the Nasdaq composite was up 210.74 points at 19,975.62. The Canadian dollar traded for 69.50 cents US compared with 69.47 cents US on Monday. The February crude oil contract was up 91 cents at US$70.15 per barrel and the February natural gas contract was up 13 cents at US$3.48 per mmBTU. The February gold contract was down US$1.10 at US$2,627.10 an ounce and the March copper contract was up two cents at US$4.11 a pound. This report by The Canadian Press was first published Dec. 24, 2024. Companies in this story: (TSX:GSPTSE, TSX:CADUSD) The Canadian Press
Air India orders 34 training aircraft for flight school
Social media erupts after Jack Smith files to dismiss Jan. 6 charges against TrumpNEW YORK , Nov. 22, 2024 /PRNewswire/ -- Monport Laser, an industry-leading brand of laser cutters and engravers, proudly announces the release of the Monport MEGA, the world's first 70W intelligent desktop CO2 laser engraving machine. This revolutionary product is the culmination of Monport's dedication to innovation and a reflection of its commitment to empowering creativity in America. Focusing on innovation, strength, and empowering individuals, M onport has designed the MEGA as a symbol of American ingenuity. The MEGA is poised to transform the laser engraving market by combining state-of-the-art technology with unmatched precision. The Monport MEGA is not just an engraving machine; it's a technological masterpiece designed to redefine creativity and productivity. The MEGA's compatibility with a wide range of materials—including wood, leather, glass, acrylic, and certain metals—makes it a versatile tool for both artistic and commercial applications. Whether crafting personalized gifts, producing intricate signage, or designing high-quality prototypes, the Monport MEGA rises to the challenge. The Revolution Starts with the MEGA Pre-Sale Building on the success of its first pre-sale phase, Monport is excited to extend the opportunity for new customers to reserve their Monport MEGA. The exclusive pre-sale period is open for just 40 days , making this a limited-time chance to secure the world's most advanced desktop laser engraver at an unbeatable price. Celebrating the Launch with Live Events and Exclusive Giveaways To showcase the MEGA's unparalleled capabilities, Monport will host an exclusive live-stream event on November 25, 2024 , where the machine's features and applications will be demonstrated in real-time. Participants can engage with the Monport team, ask questions, and witness the MEGA's revolutionary performance. During the live stream, attendees can enter giveaways to win exciting prizes, including: These prizes are Monport's way of celebrating the MEGA's launch and rewarding its vibrant community of creators and innovators. At its core, the Monport MEGA represents more than just a machine—it's a commitment to empowering creators, small businesses, and hobbyists to push the boundaries of design and innovation. By blending American ingenuity with groundbreaking technology, the MEGA is designed to inspire a new generation of makers and entrepreneurs. From personalized gifts and intricate artwork to business branding and industrial prototyping, the MEGA offers endless possibilities. It's the ultimate tool for those looking to turn their creative dreams into reality. The Monport MEGA is here to revolutionize laser engraving, offering unmatched performance, precision, and safety. Don't miss this opportunity to be among the first to experience the future of engraving. Visit Monport MEGA to learn more and claim your exclusive pre-sale benefits. As excitement mounts for the MEGA's launch, Monport is thrilled to announce its biggest sales event of the year—the Black Friday Blowout ! Running from November 5 to December 5, 2024 , this exclusive event offers unbeatable savings of up to $6,000 on top-tier laser engraving machines and accessories. Take advantage of bundle deals with "Buy More, Save More" offers, designed to help creators and businesses elevate their engraving capabilities while enjoying maximum savings. Whether you're looking to upgrade your setup or start your engraving journey, this once-a-year event is your chance to invest in premium tools at incredible value. Stay tuned for more details, and don't miss the opportunity to save big during Monport's Black Friday Blowout! View original content: https://www.prnewswire.com/news-releases/be-among-the-first-to-experience-mega-revolution---worlds-first-70w-intelligent-desktop-engraving-machine-302314445.html SOURCE Monport laser
HARRISBURG, Pa. (AP) — Former Philadelphia Eagles running back Wendell Smallwood Jr. has pleaded guilty to federal fraud charges after he was accused of submitting fraudulent tax returns and applications for hundreds of thousands of dollars in COVID-19 pandemic aid programs. The signed plea agreement was approved Friday by a federal judge in Delaware. Smallwood, of Mullica Hill, New Jersey, faces sentencing in May on the three fraud charges. Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Get updates and player profiles ahead of Friday's high school games, plus a recap Saturday with stories, photos, video Frequency: Seasonal Twice a weekSAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Constellation Network, a Web3 ecosystem validated by the US Department of Defense, today announced the launch of a customized blockchain developed in partnership with the Common Crawl Foundation, to create the industry's first cryptographically secure, immutable archive of internet data for AI training and development. The collaboration introduces a new approach to validating and securely accessing 17 years of internet crawl data-spanning nearly 9 petabytes which 80% of Large Language Models (LLMs) use to train AI-through an immutable, cryptographically secured blockchain network built on Constellation. This innovative application-specific network, or Metagraph, addresses pressing concerns in AI development while exploring vast new use cases for blockchain technology in emerging industries: data provenance, privacy, and ethical sourcing. Furthermore, the network will utilize Constellation's DAG utility asset to secure the archived internet crawls. This represents a significant advancement in utilizing cryptocurrency as a mechanism for businesses to notarize data, shifting the focus from consumer costs or gas fees typical of many other layer-one networks to an operational expense. Key Technological Innovations Industry Applications The blockchain-enabled data archive is already attracting attention from advanced AI research initiatives. TraceAI, a project developed through the National Science Foundation (NSF) and SBIR program, is in testing stages in the development of their own application-specific network, built on Constellation, to add immutability, auditability, and proof of authorship to its training models and to develop advanced watermarking technologies. TraceAI will also leverage Common Crawl's Constellation-built solution to further extend their work in blockchain encrypted AI to include tracking the source origin of data. Kevin Jackson, Vice President of Space Domain Communications & Commercialization for Forward EdgeAI, emphasizes the significance of this breakthrough: "This represents the natural evolution of AI and machine learning model development-transforming data management from a technical challenge to a trusted business tool that drives global standardization and verification." Looking Forward Over the coming months, Constellation Network and Common Crawl Foundation will work together to expand on solution sets for AI developers and further integrate the distribution of the cryptographically validated access to the crawl as part of the standard release process. "For users of the Crawl who are concerned about the provenance of the data, especially those using it for AI models, Constellation and their hypergraph blockchain provides an elegant solution”, said Rich Skrenta, Executive Director of the Common Crawl, "we are looking forward to adding the ability to securely validate the crawl as part of our standard distribution by partnering with Constellation”. Evidence of this integration can be found on Constellation's transaction viewer, called the "DAG explorer,” and developers can get started using verified historical crawls for AI applications. Please follow along for further solutions to be developed by Constellation, Forward Edge-AI, and Common Crawl. About Constellation Network Constellation is a leading blockchain network advancing innovation through on-chain data security, partnering with critical global stakeholders, including the U.S. Department of Defense, to deliver transformative, next-generation technologies. About Common Crawl Foundation The Common Crawl Foundation is a 501(c)(3) non-profit organization dedicated to providing a copy of the internet to the public, free of charge. Their web archive consists of petabytes of data collected over years of web crawling, serving as a critical resource for researchers, businesses, and developers worldwide. About Forward Edge-AI Forward Edge-AI is at the forefront of a revolution in responsible and inclusive Artificial Intelligence (AI) for the betterment of humanity. Since its foundation in 2019, our goal is to become the dominant player in Artificial Intelligence and lead the revolution in augmenting edge technology with human intelligence. About Common Crawl Foundation Contact Email: [email protected] Website: https://constellationnetwork.io/ Twitter: https://x.com/conste11ation GitHub: https://github.com/Constellation-Labs/tessellation DAG Explorer: https://mainnet.dagexplorer.io/ Contact Dagnum PI [email protected] A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/aed92cb9-444b-4b50-9a0b-5ee1889af9ea
Friday, December 20, 2024 LG Electronics USA, a leader in hospitality display solutions, has been honored with the prestigious Vacation Rental Technology Innovation Award for its revolutionary “Pro:Centric Stay” smart TV platform. The award was presented at the 2024 Vacation Rental Data and Revenue Management (DARM) Conference. Jacob Benner, Senior Director of Hospitality at LG Electronics USA, shared that LG was among 10 companies competing in the conference’s highly anticipated “DARM Battleground” segment. Each participant delivered a five-minute product pitch to an audience of over 500 attendees and a panel of three judges from the vacation rental property management industry. The presentations were followed by a six-minute Q&A session with the judging panel. “LG’s Doug Strachota did an outstanding job presenting the unique capabilities and benefits of the LG Pro:Centric Stay TV platform during the Battleground session,” Benner said. “We’re honored that the judges agreed!” The LG Pro:Centric Stay platform is a user-friendly, cloud-based solution tailored for property managers in the vacation rental industry. It seamlessly integrates property management capabilities, enabling remote control of properties and efficient guest management, all within one system. This next-generation platform merges a premium TV experience with advanced property management and guest engagement tools. Pro:Centric Stay enhances brand visibility, fosters repeat visits, improves guest communication, streamlines operational workflows, and creates opportunities for revenue growth through service upsells. The sixth annual Vacation Rental Data and Revenue Management (DARM) Conference, held from December 2-4 at the Hilton Sandestin Beach Golf Resort & Spa in Miramar Beach, Florida, gathered hundreds of industry professionals. With over 90 educational sessions, inspiring keynotes, and the popular DARM Battleground competition, the event attracted executives, revenue managers, marketers, and tech leaders. Educational tracks covered topics such as foundational and advanced revenue management, data and reporting, marketing and distribution, technology and AI, risk and revenue strategies, and executive-level discussions. LG Electronics USA was named a Gold Partner for the 2024 conference, further solidifying its commitment to innovation in the vacation rental space.Believe it or not, Cowboys might have hope yet after chaotic win at Washington
Defence Minister Bill Blair "ready to go faster" on spending timelineThe former candidate for the Bayamón senatorial district will have the task of reorganizing the party November 25, 2024 - 4:12 PM César A. Vázquez Muñiz , former senatorial candidate for Proyecto Dignidad in Bayamón , returned to the presidency of that political party after a meeting of its governing council in which former gubernatorial candidate Javier Jiménez transferred the presidency to him. In a U.S. publication, Pablo José Hernández claims to put aside the statehood debate Ana Escobar defends decisions amid Department of Corrections controversies Jenniffer González is in no hurry to announce appointments: “It’s about making a good selection”
Maropost extends its "High Performer" streak in G2 Winter Reports while earning new "Easiest to Use" badge
Nearly half of American teenagers say they are online "constantly" despite concerns about the effects of social media and smartphones on their mental health, according to a new report published Thursday by the Pew Research Center. As in past years, YouTube was the single most popular platform teenagers used — 90% said they watched videos on the site, down slightly from 95% in 2022. Nearly three-quarters said they visit YouTube every day. There was a slight downward trend in several popular apps teens used. For instance, 63% of teens said they used TikTok, down from 67% and Snapchat slipped to 55% from 59%. This small decline could be due to pandemic-era restrictions easing up and kids having more time to see friends in person, but it's not enough to be truly meaningful. X saw the biggest decline among teenage users. Only 17% of teenagers said they use X, down from 23% in 2022, the year Elon Musk bought the platform. Reddit held steady at 14%. About 6% of teenagers said they use Threads, Meta's answer to X that launched in 2023. Meta's messaging service WhatsApp was a rare exception in that it saw the number of teenage users increase, to 23% from 17% in 2022. Pew also asked kids how often they use various online platforms. Small but significant numbers said they are on them "almost constantly." For YouTube, 15% reported constant use, for TikTok, 16% and for Snapchat, 13%. As in previous surveys, girls were more likely to use TikTok almost constantly while boys gravitated to YouTube. There was no meaningful gender difference in the use of Snapchat, Instagram and Facebook. Roughly a quarter of Black and Hispanic teens said they visit TikTok almost constantly, compared with just 8% of white teenagers. The report was based on a survey of 1,391 U.S. teens ages 13 to 17 conducted from Sept. 18 to Oct. 10, 2024.NEW YORK , Nov. 22, 2024 /PRNewswire/ -- Monport Laser, an industry-leading brand of laser cutters and engravers, proudly announces the release of the Monport MEGA, the world's first 70W intelligent desktop CO2 laser engraving machine. This revolutionary product is the culmination of Monport's dedication to innovation and a reflection of its commitment to empowering creativity in America. Focusing on innovation, strength, and empowering individuals, M onport has designed the MEGA as a symbol of American ingenuity. The MEGA is poised to transform the laser engraving market by combining state-of-the-art technology with unmatched precision. The Monport MEGA is not just an engraving machine; it's a technological masterpiece designed to redefine creativity and productivity. The MEGA's compatibility with a wide range of materials—including wood, leather, glass, acrylic, and certain metals—makes it a versatile tool for both artistic and commercial applications. Whether crafting personalized gifts, producing intricate signage, or designing high-quality prototypes, the Monport MEGA rises to the challenge. The Revolution Starts with the MEGA Pre-Sale Building on the success of its first pre-sale phase, Monport is excited to extend the opportunity for new customers to reserve their Monport MEGA. The exclusive pre-sale period is open for just 40 days , making this a limited-time chance to secure the world's most advanced desktop laser engraver at an unbeatable price. Celebrating the Launch with Live Events and Exclusive Giveaways To showcase the MEGA's unparalleled capabilities, Monport will host an exclusive live-stream event on November 25, 2024 , where the machine's features and applications will be demonstrated in real-time. Participants can engage with the Monport team, ask questions, and witness the MEGA's revolutionary performance. During the live stream, attendees can enter giveaways to win exciting prizes, including: These prizes are Monport's way of celebrating the MEGA's launch and rewarding its vibrant community of creators and innovators. At its core, the Monport MEGA represents more than just a machine—it's a commitment to empowering creators, small businesses, and hobbyists to push the boundaries of design and innovation. By blending American ingenuity with groundbreaking technology, the MEGA is designed to inspire a new generation of makers and entrepreneurs. From personalized gifts and intricate artwork to business branding and industrial prototyping, the MEGA offers endless possibilities. It's the ultimate tool for those looking to turn their creative dreams into reality. The Monport MEGA is here to revolutionize laser engraving, offering unmatched performance, precision, and safety. Don't miss this opportunity to be among the first to experience the future of engraving. Visit Monport MEGA to learn more and claim your exclusive pre-sale benefits. As excitement mounts for the MEGA's launch, Monport is thrilled to announce its biggest sales event of the year—the Black Friday Blowout ! Running from November 5 to December 5, 2024 , this exclusive event offers unbeatable savings of up to $6,000 on top-tier laser engraving machines and accessories. Take advantage of bundle deals with "Buy More, Save More" offers, designed to help creators and businesses elevate their engraving capabilities while enjoying maximum savings. Whether you're looking to upgrade your setup or start your engraving journey, this once-a-year event is your chance to invest in premium tools at incredible value. Stay tuned for more details, and don't miss the opportunity to save big during Monport's Black Friday Blowout! View original content: https://www.prnewswire.com/news-releases/be-among-the-first-to-experience-mega-revolution---worlds-first-70w-intelligent-desktop-engraving-machine-302314445.html SOURCE Monport laserT The tradition is named after two significant dates: December 12th, honoring the Virgin of Guadalupe, and January 6th, celebrating the Epiphany, also known as Día de Reyes. The marathon consists of various festivities that include Posadas (nine days of celebrations leading up to Christmas), Christmas Eve, Christmas Day, New Year’s Eve, New Year’s Day, and Three Kings’ Day. Each of these days has its own set of customs and traditions that vary by region and family. The “drinking marathon” aspect of Guadalupe-Reyes is somewhat tongue-in-cheek, reflecting the social nature of the season. Friends and family gather frequently for meals, parties, and events where alcohol is often present. Traditional Mexican beverages such as tequila, mezcal, Ponche (a warm fruit punch), and Rompope (a kind of eggnog) are commonly enjoyed. The idea is to celebrate continuously, embracing the spirit of togetherness and joy. While the concept of a “marathon” might imply a test of endurance, the focus is more on enjoying the season’s festivities rather than an actual contest. It’s a playful acknowledgment of the bustling holiday schedule filled with social engagements. Despite its focus on fun and celebration, it’s always important to drink responsibly and be mindful of health and safety during this festive period. In essence, the Guadalupe-Reyes marathon encapsulates the vibrant and joyous nature of Mexican holiday traditions, providing a perfect blend of religious observance and communal celebration.
New Delhi, Nov 22 (PTI) A total of 921 degrees was awarded at the seventh convocation ceremony of Indira Gandhi Delhi Technical University for Women (IGDTUW) on Friday. The convocation was attended by LG V K Saxena, who serves as the chancellor of the university, and Delhi Chief mMinister Atishi as the Guest of Honour. During the ceremony, 735 undergraduate, 170 postgraduate and 16 doctorate degrees were awarded. The event also witnessed the awarding of two Chancellor Gold Medals and 12 Vice-Chancellor Gold Medals to the top-performing students across various disciplines. Speaking at the ceremony, Saxena lauded IGDTUW’s progress, calling it “a remarkable institution nurturing skilled female engineers.” “Empowering women is the key to building a developed nation. IGDTUW is rapidly growing and establishing its presence across the country. We have high expectations from its graduates, who have acquired valuable skills and knowledge during their time at this esteemed institution,” he added. Chief Minister Atishi highlighted the university’s role in preparing professionals, stating, “You are ready to face the world and drive progress”. “It fills me with immense pride to address you on this momentous occasion of your convocation. Today marks the culmination of years of hard work, dedication, and growth and as you step into the world as innovators, leaders, and problem solvers, remember that you are the torchbearers of tomorrow’s progress,” She said. Vice-Chancellor Ranjana Jha expressed pride, stating, “It is a matter of immense pride to acknowledge that the University has realised its vision of establishing a high-quality, research-led institute with a focus on technology, management, architecture, humanities, and allied areas for female students.” PTI SHB SHB TIR TIR This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content. var ytflag = 0;var myListener = function() {document.removeEventListener('mousemove', myListener, false);lazyloadmyframes();};document.addEventListener('mousemove', myListener, false);window.addEventListener('scroll', function() {if (ytflag == 0) {lazyloadmyframes();ytflag = 1;}});function lazyloadmyframes() {var ytv = document.getElementsByClassName("klazyiframe");for (var i = 0; i < ytv.length; i++) {ytv[i].src = ytv[i].getAttribute('data-src');}} Save my name, email, and website in this browser for the next time I comment. Δ document.getElementById( "ak_js_1" ).setAttribute( "value", ( new Date() ).getTime() );